Clinical AI · Epilepsy · Nature Medicine
Human–AI epilepsy platform: patient feedback cuts seizure false alarms ~80% (Nature Medicine / Penn / NIH)
An inpatient prototype linked scalp and intracranial EEG to a HIPAA-compliant LLM smartphone app in 13 epilepsy-monitoring-unit patients. Patients annotated detections, and a pseudoprospective simulation showed that fine-tuning the seizure detector on patient labels alone cut false alarms by about 80% while preserving sensitivity. Per the NIH release, patients exchanged more than 1,300 messages and the data agent was about 92% accurate on brain-activity questions.
Caveat: Small single-center inpatient feasibility study (n=13); not an outpatient deployment; investigational research platform, not an approved device.
Nature Medicine →
NIH news release →
Longevity · Aging clocks · Nature Biotechnology
Proteomic aging clocks enter the clinic: all six clocks read younger on rentosertib in Phase 2a IPF
A Nature Biotechnology News & Views (Oct 13) highlights the first multi-clock clinical use. The primary open-access analysis of serum proteomes from the 12-week Phase 2a trial of rentosertib, an AI-designed TNIK inhibitor (n=42 proteomic consenters), found all six proteomic clocks predicted lower biological age in treated arms vs placebo, most consistently at week 4 on 30 mg BID. The authors stress that clocks alone cannot separate anti-aging from anti-fibrotic effects.
Caveat: Ancillary analysis in IPF only; company-affiliated coauthors; not an aging indication or an approved geroprotector; disease vs aging signal not fully deconvoluted.
Nature Biotechnology News & Views →
Nature Biotechnology (primary) →
AI drug design · Autoimmunity · Insilico Medicine
AI-designed oral VAV1 molecular glue ISM9546 nominated as preclinical candidate for IBD/RA (Insilico)
Insilico used its generative Pharma.AI / Chemistry42 platform to nominate an orally bioavailable, peripherally restricted VAV1 molecular-glue degrader aimed at previously “undruggable” immune signaling. The company reports sub-nanomolar cellular degradation, about 60% improvement in histopathology scores in IBD animal models, and low brain exposure in PK studies.
Caveat: Preclinical candidate nomination only; company press release; no human data; not a therapy or approved drug.
PR Newswire →
Insilico Medicine →
Clinical AI · Pancreatic cancer · Digital twins
Blinded PASS-01 test: Concr digital twins predict chemo disease control in metastatic pancreatic cancer
UHN Toronto independently scored Concr’s FarrSight Bayesian “digital twin” predictions, made without access to outcomes, for patients in the randomized first-line PASS-01 chemotherapy trial: AUC 74% overall and 78% for mFOLFIRINOX among assessable cases (115/160). Patients predicted to achieve disease control did so 76% of the time vs 48% when predicted not to. The work builds on the earlier Frontiers AI COMPASS study.
Caveat: External model challenge on a company platform; not a validated companion diagnostic; does not replace clinical judgment; a larger validation manuscript is still under review per the release.
Cambridge Enterprise →
